Tonix Pharmaceuticals Holding Corp TNXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Trading Information
- Previous Close Price
- $3.87
- Day Range
- $3.21–3.96
- 52-Week Range
- $3.21–20.56
- Bid/Ask
- $3.24 / $3.30
- Shares Outstanding
- 19.43M
- Market Cap
- $62.96M
- Volume/Avg
- 2M / 731,128
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.tonixpharma.com
Valuation
Metric | TNXP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | 1.36 |
Price/Cash Flow | — |
Price/Earnings
TNXP
Financial Strength
Metric | TNXP |
|---|---|
Quick Ratio | 4.33 |
Current Ratio | 4.57 |
Interest Coverage | — |
Quick Ratio
TNXP
Profitability
Metric | TNXP |
|---|---|
Return on Assets (Normalized) | −67.49% |
Return on Equity (Normalized) | −77.02% |
Return on Invested Capital (Normalized) | −79.07% |
Return on Assets
TNXP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|RSWMQ@Y | LOCK|$$VR | $139B | |||
| Moderna Inc MRNA | LOCK|BB^@ljN | LOCK|B% | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<?<@%? | LOCK|>$@xF | $99B | |||
| argenx SE ADR ARGX | LOCK|XykK$z^ | LOCK|@gy | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!xPkMbz | LOCK|R># | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|BCG?<XyQ | LOCK|cKs# | $31B | |||
| Incyte Corp INCY | LOCK|d^%b$F | LOCK|@G | $25B | |||
| BioNTech SE ADR BNTX | LOCK|NK#Jm@> | LOCK|XC | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|hXTQC? | LOCK|%@FK | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|FKQ<q%w | LOCK|@x< | $16B |
United States